#COVID19

Health Check Q1 FY 21

The healthcare industry is at the centre of a new world defined by the COVID-19 pandemic – be it healthcare delivery system that cares for those infected, while exposing themselves to the virus, or the drug manufacturing industry, which is racing towards finding a cure/vaccine for the disease.

The epicentre of the disease has shifted through 2020 and India may soon find itself on the top of the table.

The economic impact of COVID-19 on world economies, particularly India, can be a cause for concern. However, the pharmaceutical industry has maintained stable revenues in 2020 compared with similar periods last year.

In terms of performance, the major listed companies* had a flat revenue growth, both over Q1 of FY 20 and the immediately preceding quarter of Q4 FY 20.

The third edition of Health Check takes a closer look at:

  • Opportunities for the pharma industry due to the ongoing pandemic
  • Impact of COVID-19 on pharma and healthcare providers
  • Government incentives available to the industry
  • Summary of Grant Thornton’s International Business Report findings from the healthcare sector

We hope you find this publication useful and informative.